These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 22664478)

  • 1. Intratumoral expression profiling of genes involved in angiogenesis in colorectal cancer patients treated with chemotherapy plus the VEGFR inhibitor PTK787/ZK 222584 (vatalanib).
    Wilson PM; Yang D; Azuma M; Shi MM; Danenberg KD; Lebwohl D; Sherrod A; Ladner RD; Zhang W; Danenberg PV; Trarbach T; Folprecht G; Meinhardt G; Lenz HJ
    Pharmacogenomics J; 2013 Oct; 13(5):410-6. PubMed ID: 22664478
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Randomized, placebo-controlled, phase III study of first-line oxaliplatin-based chemotherapy plus PTK787/ZK 222584, an oral vascular endothelial growth factor receptor inhibitor, in patients with metastatic colorectal adenocarcinoma.
    Hecht JR; Trarbach T; Hainsworth JD; Major P; Jäger E; Wolff RA; Lloyd-Salvant K; Bodoky G; Pendergrass K; Berg W; Chen BL; Jalava T; Meinhardt G; Laurent D; Lebwohl D; Kerr D
    J Clin Oncol; 2011 May; 29(15):1997-2003. PubMed ID: 21464406
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum lactate dehydrogenase levels and glycolysis significantly correlate with tumor VEGFA and VEGFR expression in metastatic CRC patients.
    Azuma M; Shi M; Danenberg KD; Gardner H; Barrett C; Jacques CJ; Sherod A; Iqbal S; El-Khoueiry A; Yang D; Zhang W; Danenberg PV; Lenz HJ
    Pharmacogenomics; 2007 Dec; 8(12):1705-13. PubMed ID: 18086000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized, placebo-controlled, phase III study of oxaliplatin, fluorouracil, and leucovorin with or without PTK787/ZK 222584 in patients with previously treated metastatic colorectal adenocarcinoma.
    Van Cutsem E; Bajetta E; Valle J; Köhne CH; Hecht JR; Moore M; Germond C; Berg W; Chen BL; Jalava T; Lebwohl D; Meinhardt G; Laurent D; Lin E
    J Clin Oncol; 2011 May; 29(15):2004-10. PubMed ID: 21464401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase IB, open-label dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer.
    Thomas AL; Trarbach T; Bartel C; Laurent D; Henry A; Poethig M; Wang J; Masson E; Steward W; Vanhoefer U; Wiedenmann B
    Ann Oncol; 2007 Apr; 18(4):782-8. PubMed ID: 17218488
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biomarkers for assessment of pharmacologic activity for a vascular endothelial growth factor (VEGF) receptor inhibitor, PTK787/ZK 222584 (PTK/ZK): translation of biological activity in a mouse melanoma metastasis model to phase I studies in patients with advanced colorectal cancer with liver metastases.
    Lee L; Sharma S; Morgan B; Allegrini P; Schnell C; Brueggen J; Cozens R; Horsfield M; Guenther C; Steward WP; Drevs J; Lebwohl D; Wood J; McSheehy PM
    Cancer Chemother Pharmacol; 2006 Jun; 57(6):761-71. PubMed ID: 16172907
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase 1 study of PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor, for the treatment of acute myeloid leukemia and myelodysplastic syndrome.
    Roboz GJ; Giles FJ; List AF; Cortes JE; Carlin R; Kowalski M; Bilic S; Masson E; Rosamilia M; Schuster MW; Laurent D; Feldman EJ
    Leukemia; 2006 Jun; 20(6):952-7. PubMed ID: 16617323
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene expression of vascular endothelial growth factor A, thymidylate synthase, and tissue inhibitor of metalloproteinase 3 in prediction of response to bevacizumab treatment in colorectal cancer patients.
    Watanabe T; Kobunai T; Yamamoto Y; Matsuda K; Ishihara S; Nozawa K; Iinuma H; Ikeuchi H
    Dis Colon Rectum; 2011 Aug; 54(8):1026-35. PubMed ID: 21730794
    [TBL] [Abstract][Full Text] [Related]  

  • 9. TS and ERCC-1 mRNA expressions and clinical outcome in patients with metastatic colon cancer in CONFIRM-1 and -2 clinical trials.
    Grimminger PP; Shi M; Barrett C; Lebwohl D; Danenberg KD; Brabender J; Vigen CL; Danenberg PV; Winder T; Lenz HJ
    Pharmacogenomics J; 2012 Oct; 12(5):404-11. PubMed ID: 21788964
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.
    Tyagi P
    Clin Colorectal Cancer; 2005 May; 5(1):24-6. PubMed ID: 15929803
    [No Abstract]   [Full Text] [Related]  

  • 11. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies.
    Morgan B; Thomas AL; Drevs J; Hennig J; Buchert M; Jivan A; Horsfield MA; Mross K; Ball HA; Lee L; Mietlowski W; Fuxuis S; Unger C; O'Byrne K; Henry A; Cherryman GR; Laurent D; Dugan M; Marmé D; Steward WP
    J Clin Oncol; 2003 Nov; 21(21):3955-64. PubMed ID: 14517187
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The histone deacetylase inhibitor NVP-LAQ824 inhibits angiogenesis and has a greater antitumor effect in combination with the vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584.
    Qian DZ; Wang X; Kachhap SK; Kato Y; Wei Y; Zhang L; Atadja P; Pili R
    Cancer Res; 2004 Sep; 64(18):6626-34. PubMed ID: 15374977
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PTK 787/ZK 222584, a tyrosine kinase inhibitor of all known VEGF receptors, represses tumor growth with high efficacy.
    Hess-Stumpp H; Haberey M; Thierauch KH
    Chembiochem; 2005 Mar; 6(3):550-7. PubMed ID: 15742376
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vascular endothelial growth factor receptor tyrosine kinase inhibitors: PTK787/ZK 222584.
    Thomas AL; Morgan B; Drevs J; Unger C; Wiedenmann B; Vanhoefer U; Laurent D; Dugan M; Steward WP
    Semin Oncol; 2003 Jun; 30(3 Suppl 6):32-8. PubMed ID: 12802793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The inhibition of tyrosine kinase receptor signalling in leiomyosarcoma cells using the small molecule kinase inhibitor PTK787/ZK222584 (Vatalanib®).
    Gaumann AK; Drexler HC; Lang SA; Stoeltzing O; Diermeier-Daucher S; Buchdunger E; Wood J; Bold G; Breier G
    Int J Oncol; 2014 Dec; 45(6):2267-77. PubMed ID: 25340839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of vascular gene expression in arthritic synovium by laser-mediated microdissection.
    Hashimoto A; Tarner IH; Bohle RM; Gaumann A; Manetti M; Distler O; Steinmeyer J; Ulfgren AK; Schulz A; Gay S; Müller-Ladner U; Neumann E
    Arthritis Rheum; 2007 Apr; 56(4):1094-105. PubMed ID: 17393418
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibition of multiple vascular endothelial growth factor receptors (VEGFR) blocks lymph node metastases but inhibition of VEGFR-2 is sufficient to sensitize tumor cells to platinum-based chemotherapeutics.
    Sini P; Samarzija I; Baffert F; Littlewood-Evans A; Schnell C; Theuer A; Christian S; Boos A; Hess-Stumpp H; Foekens JA; Setyono-Han B; Wood J; Hynes NE
    Cancer Res; 2008 Mar; 68(5):1581-92. PubMed ID: 18316624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lactate dehydrogenase 5 expression in operable colorectal cancer: strong association with survival and activated vascular endothelial growth factor pathway--a report of the Tumour Angiogenesis Research Group.
    Koukourakis MI; Giatromanolaki A; Sivridis E; Gatter KC; Harris AL;
    J Clin Oncol; 2006 Sep; 24(26):4301-8. PubMed ID: 16896001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab.
    Loupakis F; Cremolini C; Yang D; Salvatore L; Zhang W; Wakatsuki T; Bohanes P; Schirripa M; Benhaim L; Lonardi S; Antoniotti C; Aprile G; Graziano F; Ruzzo A; Lucchesi S; Ronzoni M; De Vita F; Tonini G; Falcone A; Lenz HJ
    PLoS One; 2013; 8(7):e66774. PubMed ID: 23861747
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials.
    Drevs J; Zirrgiebel U; Schmidt-Gersbach CI; Mross K; Medinger M; Lee L; Pinheiro J; Wood J; Thomas AL; Unger C; Henry A; Steward WP; Laurent D; Lebwohl D; Dugan M; Marmé D
    Ann Oncol; 2005 Apr; 16(4):558-65. PubMed ID: 15705616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.